Key Points
- United Therapeutics COO Michael Benkowitz sold 22,500 shares on Feb. 9 at an average price of $474.65, generating about $10.68 million in proceeds.
- Benkowitz has sold repeatedly since mid‑December — roughly 202,500 shares in total for about $98.2 million across multiple transactions, signaling significant insider selling activity.
- UTHR trades near $473 with a market cap of about $20.4 billion, and analysts' consensus is a “Moderate Buy” with an average target price of approximately $509.50.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Michael Benkowitz also recently made the following trade(s):
- On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00.
- On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $6,795,652.50.
- On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total value of $3,659,197.50.
- On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $471.91, for a total value of $10,617,975.00.
- On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total value of $10,788,975.00.
- On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $3,838,117.50.
- On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
- On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
- On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
- On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00.
United Therapeutics Stock Up 0.0%
Shares of UTHR stock opened at $473.20 on Wednesday. The firm has a market cap of $20.38 billion, a P/E ratio of 17.93, a PEG ratio of 2.52 and a beta of 0.85. The company has a 50 day moving average of $486.59 and a 200-day moving average of $430.69. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.
Hedge Funds Weigh In On United Therapeutics
Institutional investors have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics during the fourth quarter valued at about $31,000. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter worth about $48,000. Institutional investors own 94.08% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have issued reports on UTHR. Jefferies Financial Group restated a "buy" rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 30th. HC Wainwright upped their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a research note on Thursday, October 30th. UBS Group raised their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $509.50.
Check Out Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
